Internal Medicine Alert – May 30, 2024
May 30, 2024
View Issues
-
Inappropriate Diagnosis of Pneumonia Is Common in Hospitalized Patients
A cohort study that included 48 hospitals in Michigan found that 12% of patients treated for community-acquired pneumonia were diagnosed inappropriately. Older age, dementia, and presenting with acute change in mental status increased the risk for misdiagnosis.
-
The Burden of Clostridioides difficile Infection
This article outlines the clinical, social, and economic burden of Clostridioides difficile infection (CDI) in the United States and its shifting epidemiology.
-
Increased Risk of Morbidity with Prolonged Use of PPIs Without an Indication Post-ICU
In previously critically ill adults, the use of a proton pump inhibitor without an indication for more than eight weeks increased morbidity and mortality.
-
Another Step in the Journey to Combat Diagnostic Errors in Hospitalized Patients
Diagnostic errors in hospitalized patients who died or were transferred to the intensive care unit were common in this large retrospective, multicenter trial and frequently associated with patient harm. Problems with clinical assessment and ordering and interpreting tests were the most prevalent diagnostic process faults, with sepsis the diagnosis most associated with diagnostic error.
-
Ceftobiprole Medocaril Sodium for Injection (Zevtera)
The U.S. Food and Drug Administration has approved a new cephalosporin antibacterial for the treatment of three serious infections: bloodstream, skin and skin structure, and community-acquired pneumonia. Ceftobiprole is a fifth-generation cephalosporin with in vitro activity against gram-positive and gram-negative bacteria including multidrug resistant organisms. It will be distributed by Basilea Pharmaceutica International Ltd, Allschwil as Zevtera.